PlainPharmaWatch

CMS Open Payments · Program Year 2024

Biocartis US, Inc

Biocartis US, Inc reported $9,174.02 in payments to 16 physicians and teaching hospitals across 16 transactions.

See the rankings → How this is sourced
$9.2K
Total payments
16
Transactions
16
Recipients
+$376.13
General Payments vs PY2023

Biocartis US, Inc reported $9,174.02 in payments to 16 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #1653 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $573.38 per recipient across 2 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Biocartis US, Inc pairs modest payment volume with a moderately concentrated payment pattern.

#1653
of 1,925 companies
0.0%
of all US industry payments
0.4%
paid to its single top recipient
2
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Biocartis US, Inc's CMS-reported General Payments increased by $376.13 (+4.3%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: BIOCARTIS US, INCPY2023: BIOCARTIS US, INCPY2024: Biocartis US, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$8.8KPY2024$9.2K
PY2023
$8,797.89
PY2024
$9,174.02

How Biocartis US, Inc ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Biocartis US, Inc's total vs. every reporting company

CMS Open Payments, Program Year 2024

$9,174 14th percentile higher than 14% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). This entry sits in this band. $25,112–$78,003: 249 reporting companies (13%). Above this entry. $78,003–$242,294: 295 reporting companies (15%). Above this entry. $242,294–$752,621: 270 reporting companies (14%). Above this entry. $752,621–$2,337,813: 263 reporting companies (14%). Above this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Biocartis US, Inc

Rank #1653 of 1,925 companies in CMS Open Payments for 2024 belongs to Biocartis US, Inc, which reported $9,174.02 across 16 transactions to 16 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $573.38 per transaction and $573.38 per recipient.

4 transactions worth $6.7K make "Consulting Fee" the top general-payment category in the 2-category breakdown below, 73.3% of the reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Consulting Fee" leads Biocartis US, Inc's 2-category general-payment breakdown at $6.7K, 73.3% of the reported total.

How Biocartis US, Inc divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$6.7K2. Food and Beverage$2.4K
Payment Type Amount Transactions
Consulting Fee $6.7K 4
Food and Beverage $2.4K 12

Recipient Concentration in General Payments

The five largest recipient relationships account for $8,372.67 (91.3%) of $9,174.02 in this company's General Payments records across 11 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Biocartis US, Inc

The five named recipients with the highest reported General Payments from this company

Zoran Gatalica$3.8KGloria Sura$3.0KRoshan Patel$568.85Orin Buetens$546.61Ian Bovio$530.31
  1. 1

    Zoran Gatalica

    $3,750.00 across 2 reported transactions

  2. 2

    Gloria Sura

    $2,976.90 across 2 reported transactions

  3. 3

    Roshan Patel

    $568.85 across 3 reported transactions

  4. 4

    Orin Buetens

    $546.61 across 1 reported transactions

  5. 5

    Ian Bovio

    $530.31 across 2 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $573.38. Average per recipient: $573.38.

Total Amount

$9,174.02

Avg per Transaction

$573.38

Avg per Recipient

$573.38

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Biocartis US, Inc Share

0.0%

#1653 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Biocartis US, Inc

G21 Srl

$9.2K 9 recipients

Myomo, Inc

$9.3K 14 recipients

Digestive Care, Inc.

$9.0K 333 recipients

Avvisto Therapeutics, LLC

$8.9K 478 recipients

Auxano Medical LLC

$8.8K 10 recipients

Oak Med, Inc.

$9.5K 106 recipients

Frequently Asked Questions

How much did Biocartis US, Inc pay to physicians and hospitals in 2024? ▾
0.0% of all industry payments reported to CMS Open Payments for 2024 came from Biocartis US, Inc, totaling $9,174.02 across 16 transactions to physicians and hospitals.
How many physicians received payments from Biocartis US, Inc? ▾
Biocartis US, Inc made payments to 16 physicians and teaching hospitals in 2024. The average payment per recipient was $573.38.
What types of payments did Biocartis US, Inc make? ▾
Biocartis US, Inc made 2 different types of general payments (consulting, meals, travel, and similar categories). The largest general-payment category was "Consulting Fee" at $6.7K, representing 73.3% of the company's reported total.
How does Biocartis US, Inc rank among pharmaceutical companies? ▾
By total payment amount, Biocartis US, Inc sits at #1653 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Biocartis US, Inc? ▾
The average transaction from Biocartis US, Inc was $573.38 in 2024. The company made 16 total transactions to 16 recipients.
Where does the payment data for Biocartis US, Inc come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Biocartis US, Inc's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.